
Opinion|Videos|March 6, 2025
Consolidation Durvalumab in Unresectable Stage III NSCLC: Management Strategies and the Role of ctDNA
This video discusses evolving treatment paradigms for locally advanced lung cancer, highlighting the impact of trials like PACIFIC on the role of chemoradiotherapy and consolidation therapy with durvalumab, the potential integration of circulating tumor DNA (ctDNA) for personalized treatment decisions, and the implications for both surgical and nonsurgical patient populations.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How do you select patients for consolidation durvalumab?
Advertisement
Related to this article

The FDA approved giredestrant plus everolimus in ESR1-mutated breast cancer and neladalkib in ALK+ NSCLC, issued a CRL to ivonescimab, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The EC approved every-6-week maintenance dosing and shorter 350-mg infusions for cemiplimab across all 6 EU indications.

Faculty convened at an OncLive Scientific Interchange and Workshop to guide oncology fellows through designing a cancer clinical trial development program, from concept to approval.

Narek Shaverdian, MD, outlines how novel strategies may reshape unresectable stage III NSCLC management.

The FDA granted fast track designation to elticertinib for pretreated EGFR exon 20 insertion–mutated NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Plus Gemcitabine/Nab-Paclitaxel Generates Durable Responses in First-Line Metastatic PDAC
2
TroFuse-015 Meets Primary OS End Point With Sac-TMT in Third-Line or Later Gastroesophageal Adenocarcinoma
3
Dr Iyengar on Oral SERD Implementation in Early-Stage HR+ Breast Cancer
4
Dr Gutierrez on Considerations for Investigating SAR445877 in MSS CRC
5


